2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1200

Anti-Cyclic Citrullinated Peptide Antibodies in Idiopathic Pulmonary Fibrosis Are Not Citrulline-Specific: Implications for the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 325

Anti-Cyclic Citrullinated Peptide Antibody Isotyping and Identification of Citrullinated Proteins in the Synovial Fluid of Juvenile Idiopathic Arthritis Patients
Abstract Number: 2156

Anti-Cyclic Citrullinated Protein Antibodies As a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis A Prospective Study
Abstract Number: 1211

ANTI-Cyclic Citrullinated Protein Antibodies Induce Inflammation and Oxidative Stress in WHITE Blood CELLS of Rheumatoid Arthritis Patients
Abstract Number: 2598

Anti-Drug Antibodies Are Associated with Diminished Drug Levels and Treatment Failure
Abstract Number: 854

Anti-EIF2B: A Novel Interstitial Lung Disease Associated Autoantibody in Patients with Systemic Sclerosis
Abstract Number: 1725

ANTI-Factor Xa Antibodies ARE Significantly Increased in Patients with Systemic LUPUS Erythematosus and Antiphospholipid Syndrome
Abstract Number: 1796

Anti-IL-20 Targets Local Tissue Inflammation As Opposed to Systemic Inflammation
Abstract Number: 1307

Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Abstract Number: 1662

Anti-IL-6 Therapy Impairs Intestinal Repair Through Inhibition of Epithelial Proliferation After Injury
Abstract Number: 882

Anti-Inflammatory Effects of Phosphodiesterase 4 Inhibition Are Mediated by Mitogen-Activated Protein Kinase Phosphatase-1
Abstract Number: 2079

Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis
Abstract Number: 1391

Anti-Ku Autoantibodies in Systemic Lupus Erythematosus Versus Autoimmune Myositis As Measured by a Novel Chemiluminescence Assay
Abstract Number: 637

Anti-Mullerian Hormone and Ovarian Reserve in Systemic Lupus Erythematosus
Abstract Number: 1403

Anti-Nucleosome Antibodies Are Associated with Disease Activity and Hydroxychloroquine Use in Patients with Lupus: A Longitudinal, Multivariate Analysis of 398 Samples

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].